No role for the CYP3A5*3 polymorphism in intestinal and hepatic metabolism of midazolam.
Tomalik-Scharte
D
D
Doroshyenko
O
O
Kirchheiner
J
J
Jetter
A
A
Lazar
A
A
Klaassen
T
T
Frank
D
D
Wyen
C
C
Fätkenheuer
G
G
Fuhr
U
U
D000284:Administration, Oral; D000328:Adult; D001682:Biological Availability; D016022:Case-Control Studies; D051544:Cytochrome P-450 CYP3A / Q000235:genetics / Q000378:metabolism*; D005260:Female; D015658:HIV Infections / Q000097:blood; D006679:HIV Seropositivity / Q000097:blood; D006801:Humans; D007275:Injections, Intravenous; D007413:Intestinal Mucosa / Q000378:metabolism*; D008099:Liver / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008874:Midazolam / Q000008:administration & dosage / Q000097:blood / Q000378:metabolism* / Q000493:pharmacokinetics; D008875:Middle Aged; D011110:Polymorphism, Genetic
C510164:CYP3A5 protein, human; D051544:Cytochrome P-450 CYP3A; D008874:Midazolam